Levoflox is a fluoroquinolone antibiotic indicated for the treatment of adults with infections caused by susceptible strains of designated microorganisms. As a synthetic broad-spectrum antibacterial agent, levofloxacin—the active ingredient in Levoflox—demonstrates excellent tissue penetration and bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens. Its mechanism of action involves inhibition of bacterial DNA gyrase and topoisomerase IV, enzymes critical for DNA replication, transcription, and repair. This product is available in oral tablet and intravenous formulations, providing flexibility in administration based on clinical severity and patient needs.

Features

• Contains levofloxacin, a third-generation fluoroquinolone antibiotic
• Available in 250mg, 500mg, and 750mg tablet strengths
• IV formulation for hospital and clinical administration
• Broad-spectrum coverage against aerobic Gram-positive and Gram-negative bacteria
• Excellent bioavailability with approximately 99% oral absorption
• Linear pharmacokinetics with dose-proportional plasma concentrations
• Penetrates well into tissues including lungs, skin, and prostate
• Bactericidal activity at concentrations near minimum inhibitory concentrations

Benefits

• Effective treatment for complicated and uncomplicated bacterial infections across multiple organ systems
• Rapid onset of action with bactericidal effects within hours of administration
• Convenient once-daily dosing regimen improves patient compliance
• Comprehensive coverage reduces need for combination antibiotic therapy
• Proven clinical efficacy in community-acquired and healthcare-associated infections
• Well-established safety profile with extensive clinical documentation

Common use

Levoflox is indicated for the treatment of adults with infections caused by susceptible strains of designated microorganisms in the following conditions: community-acquired pneumonia due to Streptococcus pneumoniae (including multidrug-resistant strains), Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae; complicated skin and skin structure infections including diabetic foot infections without osteomyelitis; uncomplicated skin and skin structure infections; chronic bacterial prostatitis; complicated urinary tract infections; acute pyelonephritis; and uncomplicated urinary tract infections.

Dosage and direction

The dosage of Levoflox and duration of therapy should be individualized based on the type and severity of infection, pathogen susceptibility, and renal function. For normal renal function (creatinine clearance ≥50 mL/min): community-acquired pneumonia—500 mg once daily for 7-14 days; complicated skin infections—750 mg once daily for 7-14 days; uncomplicated urinary tract infections—250 mg once daily for 3 days; chronic bacterial prostatitis—500 mg once daily for 28 days. Tablets should be swallowed whole with water, with or without food, at approximately the same time each day. For patients with impaired renal function, dosage adjustment is necessary based on creatinine clearance.

Precautions

Patients should be advised that Levoflox may cause dizziness and lightheadedness; therefore, caution should be exercised when driving or operating machinery. Adequate hydration should be maintained to prevent crystal formation in urine. Exposure to direct sunlight or artificial UV light should be avoided during treatment and for several days after completion due to photosensitivity risk. Tendon inflammation or rupture may occur, particularly in elderly patients and those receiving corticosteroid therapy—discontinue immediately if pain, swelling, or inflammation of a tendon occurs. Blood glucose disturbances may occur, especially in diabetic patients; monitor blood glucose regularly. Use with caution in patients with known or suspected central nervous system disorders that may predispose to seizures.

Contraindications

Levoflox is contraindicated in patients with known hypersensitivity to levofloxacin, other quinolone antibiotics, or any component of the formulation. Contraindicated in patients with history of tendon disorders related to fluoroquinolone administration. Not recommended for use in patients with known prolongation of the QT interval, those with uncorrected hypokalemia, and patients receiving Class IA or Class III antiarrhythmic agents. Should not be used in patients with myasthenia gravis due to potential for exacerbation. Pregnancy Category C: not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Not recommended for use in pediatric patients or nursing mothers.

Possible side effect

The most common adverse reactions (≥3%) include nausea, headache, diarrhea, insomnia, constipation, dizziness, and abdominal pain. Less frequent but potentially serious adverse effects may include: tendonitis and tendon rupture; peripheral neuropathy; central nervous system effects (seizures, anxiety, confusion); QT interval prolongation and ventricular arrhythmias; hypersensitivity reactions; hepatotoxicity; Clostridium difficile-associated diarrhea; blood glucose disturbances; and photosensitivity/phototoxicity reactions. Hematologic abnormalities including leukopenia and eosinophilia may occur. Renal toxicity including interstitial nephritis has been reported.

Drug interaction

Levoflox may interact with several classes of medications: antacids containing magnesium or aluminum, sucralfate, metal cations such as iron, and multivitamins containing zinc may significantly reduce absorption—administer these agents at least 2 hours before or 2 hours after Levoflox. Nonsteroidal anti-inflammatory drugs may increase the risk of CNS stimulation and seizures. May enhance effects of warfarin—monitor prothrombin time and INR closely. Corticosteroids may increase risk of tendon rupture. Drugs that prolong QT interval (antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) may have additive effects on QT prolongation. Hypoglycemic agents may require dosage adjustment due to potential for blood glucose alterations.

Missed dose

If a dose of Levoflox is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Maintaining consistent blood levels is important for therapeutic efficacy, so patients should be instructed to establish a routine for medication administration. If multiple doses are missed, contact the prescribing healthcare provider for guidance on resumption of therapy.

Overdose

In case of overdose, symptomatic and supportive care should be instituted. ECG monitoring is recommended due to potential for QT prolongation. Levoflox is not efficiently removed by hemodialysis or peritoneal dialysis. Management of overdose should include emptying gastric contents if ingestion was recent, followed by close observation and appropriate supportive measures. Maintain adequate hydration. Specific antidotes are not available. Seizures should be managed with standard anticonvulsant therapy. Renal function should be monitored, and urine alkalization may be considered to prevent crystal formation.

Storage

Store Levoflox tablets at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers, as this may affect stability. Unused medication should be properly disposed of according to local regulations or through medication take-back programs.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Levoflox is a prescription medication that should be used only under the supervision of a qualified healthcare professional. The prescribing physician should be consulted for diagnosis and treatment decisions. Individual patient response may vary, and not all side effects are listed. Patients should disclose their complete medical history and current medications to their healthcare provider before starting therapy. This information does not replace the official prescribing information provided by the manufacturer.

Reviews

Clinical studies have demonstrated Levoflox to be highly effective in the treatment of various bacterial infections. In multicenter trials involving patients with community-acquired pneumonia, clinical success rates of 92-96% were observed. For complicated skin and skin structure infections, success rates ranged from 83-91%. The once-daily dosing regimen has been particularly praised by both clinicians and patients for improving adherence compared to multiple-daily-dose antibiotics. Healthcare providers note the reliable coverage against common respiratory pathogens and the convenience of both oral and IV formulations for step-down therapy. Some reviews mention the importance of appropriate patient selection and monitoring for potential adverse effects, particularly in elderly populations and those with renal impairment.